Novo Nordisk partners on stem cell-based therapies

16 May 2018
2019_biotech_test_vial_discovery_big

Danish diabetes care giant Novo Nordisk (NOV: N) today announced an increased commitment to stem cell-based therapies and an expansion of the focus on type 1 diabetes into other serious chronic diseases.

This has been made possible through an exclusive collaboration with the University of California San Francisco (UCSF) in which a first milestone in the development of human embryonic stem cell lines has been reached.

Under the terms of the agreement with UCSF, Novo Nordisk has licensed a technology to enable the generation of Good Manufacturing Practice (GMP) compliant human embryonic stem cell (hESC) lines as well as the rights to further develop these into future regenerative medicine therapies. In early May, the partners reached an important milestone with the inauguration of a new GMP laboratory at UCSF where employees from the university and Novo Nordisk will be working together on deriving the cell lines that are expected to define a new quality standard in production of stem cell-based therapies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology